Belantamab mafodotin-blmf (Intravenous)
Medically reviewed by Drugs.com. Last updated on Mar 29, 2022.
Ocular ToxicityBelantamab mafodotin-blmf caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes.Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold belantamab mafodotin-blmf until improvement and resume, or permanently discontinue, based on severity.Because of the risk of ocular toxicity, belantamab mafodotin-blmf is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP REMS .
Commonly used brand name(s)
In the U.S.
- Blenrep
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Antibody Drug Conjugate
Uses for belantamab mafodotin-blmf
Belantamab mafodotin-blmf injection is used to treat multiple myeloma (a type of bone marrow cancer) in patients whose cancer has come back and who have received at least 4 previous treatments (eg, anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent) that did not work well.
Belantamab mafodotin-blmf is available only under a restricted distribution program called the Blenrep REMS (Risk Evaluation and Mitigation Strategy) program.
Before using belantamab mafodotin-blmf
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For belantamab mafodotin-blmf, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to belantamab mafodotin-blmf or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of belantamab mafodotin-blmf injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of belantamab mafodotin-blmf injection in the elderly.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Interactions with food/tobacco/alcohol
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcoh..
